The 50-State Network is a grassroots advocacy organization comprised of patients like you. We are working to share the patient perspective, which is crucial in the State and Federal health policy and regulatory arenas. Patients need a voice in all conversations that relate to our access to treatment, safety, or the quality of our care. This community is made up of patients living with diverse chronic illnesses, including rheumatoid arthritis, lupus, and psoriasis, and the people who care about them. The 50-State Network is about transforming pain into purpose, empowering those that may feel victimized by disease. Our focus is on repurposing the energy of frustration, despair, and helplessness into positive mobilization, action, and fair representation to benefit all of us. Our formula, which we offer to our fellow patients and their loved ones, is to take lemons and make lemonade...
July 18, 2016
On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]
July 18, 2016
GHLF in the news
The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.
July 15, 2016
The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.